Abstract
A clinical decision report using
McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: Results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology. 2016;41(5):1251-1260. https://doi.org/10.1038/npp.2015.275
for a young woman requesting a novel pharmacological intervention for a Binge Eating Disorder (BED).
DOI
10.22237/crp/1656633660
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
YOUNG B. Lisdexamfetamine is an effective monotherapy for moderate to severe binge eating disorder. Clin. Res. Prac. Jul 25 2022;8(1):eP2791. https://doi.org/10.22237/crp/1656633660
Included in
Food Science Commons, Human and Clinical Nutrition Commons, Medical Education Commons, Neuroscience and Neurobiology Commons, Translational Medical Research Commons
